share_log

千金药业(600479.SH):盐酸达泊西汀片获得药品注册证书

Zhuzhou Qianjin Pharmaceutical (600479.SH): Dapoxetine hydrochloride tablets have obtained the Pharmaceutical registration certificate.

Gelonghui Finance ·  Dec 12 17:18

On December 12, Gelonghui reported that Zhuzhou Qianjin Pharmaceutical (600479.SH) announced that its subsidiary, Hunan Qianjin Xiangjiang Pharmaceutical Co., Ltd., received the drug registration certificate for Dapoxetine Hydrochloride Tablets approved by the National Medical Products Administration. Dapoxetine is a selective serotonin reuptake inhibitor that binds to and blocks the serotonin reuptake receptors on the presynaptic membrane, increasing the concentration of serotonin in the synapse, achieving the effect of delaying ejaculation.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment